China is the global research leader in 37 of 44 critical technologies,including advanced explosives,biological manufacturing and artificial intelligence.
The blood plasma giant reaffirmed full-year guidance on Tuesday,though first-half profits saw a dip.
After a decade in the top job,CSL boss Paul Perreault weighs in on the future of mRNA,how Australia can secure a biotech boom - and how to choose an AFL team.
Moderna will lodge approval applications for a new vaccine for RSV that could be on the market as soon as next year in a big step forward in its pipeline outside of COVID.
Brisbane-based COVID-19 test maker Ellume has been snapped up by rapid test distributor Hough Pharma in a deal worth $57.1 million.
The biotech giant’s chief operating officer Paul McKenzie will start in the top job from March after Paul Perreault confirmed he will step down after a mammoth decade at the helm.
The biotech giant has amped up its plasma processing power in Victoria as it switches its focus back from COVID vaccines to specialist blood-based medicine.
Sleep treatments giant ResMed has been splashing cash on projects for growth as the sector spends up to secure post-pandemic growth.
The Aussie biotech giant will bring the first gene therapy for haemophilia B to market in the US,but the one-off treatment comes with a hefty price tag.
Australians became familiar with CSL through the pandemic,but as the company emerges from COVID,it has ambitious new plans to disrupt a variety of medical ailments.
The deal will give CSL the exclusive licence to US company Arcturus Therapeutics’ technology in the fields of influenza,COVID-19 and other respiratory diseases.